Financial Times Reports On Controversy Over Cost Of New HCV Medication

Financial Times: Hepatitis C: Treated — at a price
“…The launch in recent weeks of sofosbuvir, the first of a series of new drugs for hepatitis C virus (HCV) set for regulatory approval, raises the prospect of curing and potentially eliminating a disease that levies a heavy global burden. … Yet in one of many parallels between HCV and HIV, sofosbuvir has sparked controversy over its high price…” (Jack, 1/27).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.